Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
Okinawa is the original Blue Zone, validated by nearly five decades of groundbreaking research by ORCLS, which led to the discovery of other "longevity hotspots" - areas of the world with high concentrations of where people live to exceptional ages, extending not only their lifespans but their healthspans. KLTO has preliminary data from ORCLS suggesting the human alpha-Klotho gene and its secreted alpha-Klotho protein isoform (s-KL) may contribute to healthy longevity and lifespan. As we grow old, α-Klotho blood and tissue levels decrease. The decrease in tissue levels precedes the onset of multiple pathologies and diseases of human organ systems. Importantly, replenishing the s-KL levels using gene therapy may help protect against neurodegenerative disorders, muscle loss, bone loss and heart, liver and kidney disfunction associated with aging.
Commenting on this significant opportunity, Dr. Joseph Sinkule, the CEO of KLTO, noted that "animal studies using the Klotho gene in degenerative neurological conditions produced extremely interesting results. KLTO and ORCLS scientists believe the maintenance of optimum blood levels of the Klotho protein in later life correlates with longevity, whereas lower blood levels are associated with premature aging and a propensity to develop certain neurological disorders. While results in animal studies do not always translate into success in human clinical studies, we were very encouraged by the exceptional results, and believe that our patent protected secreted s-KL protein isoform of the Klotho gene holds real promise for the development of effective treatments for neurological disorders, as well as other age-related disorders such as sarcopenia, osteoporosis, diabetes and various renal and cardiovascular disorders. We are confident that our work with the highly experienced team of medical researchers and other well-known scientists at the ORCLS will provide groundbreaking evidence that the Klotho protein levels in humans are one of several highly critical factors for sustaining human health span, including avoidance of neurological and other age-related disorders."
Dr. Bradley Willcox, MD, MSc, FGSA, FRSM, a leading member of the Okinawa Research Center for Longevity Science, stated that "for the last 50 years, our ORCLS Team, led by Dr. Makoto Suzuki, has been producing groundbreaking research on human aging and longevity. ORCLS scientists created the world's largest, ongoing study of centenarians in the world, discovered the first human longevity genes (Lancet, 1987), and were the first to validate and translate longevity gene findings in mice and other model organisms to humans (PNAS 2008), among other notable discoveries in aging. We have collected and banked biological samples and clinical data, including blood and tissue samples over many years. A selection of these centenarian blood samples will be analyzed in the first phase of our research partnership with KLTO, where we will assess blood levels of the Klotho protein to establish the role of the Klotho protein in promoting longevity and reducing the risks of neurodegenerative diseases, such as ALS, AD and PD, as well as diabetes and cardiovascular disorders."
The Klotho gene was named after the mythologic Greek goddess, Clotho, who was said to "spin the thread of life." The Blue Zones are located in Okinawa, Japan; Ikaria, Greece; the Ogliastra Region of Sardinia; the Nicoya Peninsula in Costa Rica; and Loma Linda, USA.
About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Investor Contact and Corporate Communications –
Jeffrey LeBlanc, CFO
[email protected]
Website: www.klothoneuro.com.
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
11 hours ago
- Cision Canada
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
NEW YORK, /CNW/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies. AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often develop unnoticed by patients and might not be detected during routine exams. By identifying these signs early, AI enhances the ability to initiate treatments promptly, significantly improving health outcomes. This proactive approach allows for timely intervention, which is crucial in preventing the progression of these eye diseases. AI enhances patient care by analyzing the risk of disease progression and the specifics of each patient's retinal condition. This analysis helps healthcare providers develop customized treatment plans, tailored to individual needs. AI can predict how diseases like AMD will progress and helps in optimizing treatment schedules. This personalized approach ensures that each patient receives the most effective care specific to their condition, potentially improving their quality of life. A report from said that the Global AI-Powered Retina Image Analysis Market Size is projected to expand significantly, reaching approximately US$ 9.4 billion by 2033, up from US$ 2.65 billion in 2023. This growth, at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2033, is fueled by several pivotal developments in the field of ophthalmology, driven by advances in artificial intelligence (AI). Active healthcare/tech companies active in the diabetes treatment industry include: Avant Technologies Inc. (OTCQB: AVAI), Abbott (NYSE: ABT), DexCom, Inc. (NASDAQ: DXCM), iRhythm Technologies, Inc. (NASDAQ: IRTC), Tandem Diabetes Care, Inc. (NASDAQ: TNDM). continued: "Enhanced Patient Monitoring through AI: AI-powered tools are revolutionizing the monitoring of retinal diseases. These tools enable continuous observation, allowing doctors to track disease progression over time. This ongoing monitoring is crucial for chronic conditions, where timely adjustments to treatment can lead to better management of the disease. Continuous data collection provided by AI tools offers a dynamic view of the patient's condition, facilitating more informed decision-making in clinical practice. Expanding Access to Care with AI in Ophthalmology: AI technology can significantly extend the reach of specialized eye care, especially to remote or underserved communities. Through AI, high-quality diagnostic and monitoring services can be delivered remotely, eliminating the need for patients to travel to specialist centers. This capability not only saves time and resources but also ensures that more patients have access to necessary care, improving eye health outcomes across diverse populations. Supporting Research and Development in Ophthalmology: AI applications in retina image analysis contribute valuable data to the field of ophthalmology. This data aids in ongoing research, offering new insights into how retinal diseases develop and progress. Researchers can use this information to explore potential new treatments and understand disease mechanisms more deeply. AI's role in R&D not only accelerates scientific discovery but also opens up possibilities for innovative therapeutic approaches, enhancing patient care." Avant Technologies, Inc. (OTCQB: AVAI) and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA - Avant Technologies, Inc. ("Avant" or the "Company") and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the completion of its milestone meeting with the U.S. Food and Drug Administration (FDA). The pre-submission meeting allowed Ainnova and its Contract Research Organization (CRO), Fortrea, to present and discuss Ainnova's planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy and receive critical feedback from the FDA. Ainnova's clinical trial will be conducted exclusively in the United States and focus solely on diabetic retinopathy. The FDA has now provided the Company with valuable guidance on its clinical protocol, the number and type of clinics Ainnova will need to conduct a successful clinical trial, the number of retinologists required to examine the images generated by Ainnova's Vision AI, etc. With the FDA's recommendations, the Company can now actively plan for the total cost of conducting this planned clinical trial through to completion. Data from Ainnova's trial will support the Company's FDA 510(k) submission to obtain clearance from the FDA to market the Vision AI technology in the United States. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We're truly excited about this next phase. We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists. "This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera, which we believe will be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care." AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's clinical trial is paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product. CONTINUED… Read this and more news for Avant Technologies at: In other diabetes developments and happenings in the biotech market include: Abbott (NYSE: ABT) recently announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus* sensor, is now available to Canadians living with diabetes. This innovative product features the world's smallest1,2 glucose sensor. Glucose monitoring is key to effective diabetes management as it helps people living with diabetes understand how their body responds to food, exercise, and medications3. It empowers them to take an active role in managing their condition, which can ultimately increase confidence4 and improve health outcomes. DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, recently released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States. During the conference, Dexcom will present extensive clinical data that shows the benefits of CGM for those living with Type 2 diabetes as well as new outcomes from early Stelo users. Dexcom releases new State of Type 2 Report: Access and Attitudes Across the United States - Earlier this year, Dexcom announced the release of its first multi-region report, detailing access and attitudes of individuals diagnosed with Type 2 diabetes and healthcare professionals across Europe and the Middle East (EMEA). iRhythm Technologies, Inc. (NASDAQ: IRTC) recently announced the results from two large-scale real-world studies presented at the American Diabetes Association's 85th Scientific Sessions (ADA 2025). The analyses reveal that cardiac arrhythmias are common and often occur early in people with type 2 diabetes (T2D)—especially those who also have chronic kidney disease (CKD). These findings suggest a critical opportunity to enhance early detection strategies in at-risk cardiometabolic populations. The studies examined longitudinal claims data from over 30 million U.S. adults, providing new insights into how arrhythmias—often asymptomatic—cluster around major disease inflection points. In T2D patients, arrhythmias were frequently identified prior to or shortly after diagnoses of CKD or major adverse cardiovascular events such as stroke or heart failure. Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, recently announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs," said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. "The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology." DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU was compensated twenty two hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Cision Canada
12 hours ago
- Cision Canada
Avant Technologies and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA
LAS VEGAS, July 15, 2025 /CNW/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the completion of its milestone meeting with the U.S. Food and Drug Administration (FDA). The pre-submission meeting allowed Ainnova and its Contract Research Organization (CRO), Fortrea, to present and discuss Ainnova's planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy and receive critical feedback from the FDA. Ainnova's clinical trial will be conducted exclusively in the United States and focus solely on diabetic retinopathy. The FDA has now provided the Company with valuable guidance on its clinical protocol, the number and type of clinics Ainnova will need to conduct a successful clinical trial, the number of retinologists required to examine the images generated by Ainnova's Vision AI, etc. With the FDA's recommendations, the Company can now actively plan for the total cost of conducting this planned clinical trial through to completion. Data from Ainnova's trial will support the Company's FDA 510(k) submission to obtain clearance from the FDA to market the Vision AI technology in the United States. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We're truly excited about this next phase. We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous - comparing our AI-based retinal screening to the readings of three retinologists. "This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera, which we believe will be a game changer - making diabetic retinal screenings faster, more accessible, and available from virtually any point of care." AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's clinical trial is paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies Inc. Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at - technologies - ai Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Cision Canada
14 hours ago
- Cision Canada
Viatris Certified as a Great Place to Work® in Canada Français
ETOBICOKE, ON, /CNW/ -- Viatris Inc. (Nasdaq: VTRS) has been certified as a Great Place to Work® in Canada. This recognition highlights Viatris' commitment to fostering a culture where colleagues are enthusiastic about the work they do and feel valued, engaged and motivated. Great Place to Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. This recognition is the result of an independent evaluation, which uses a rigorous two-step process that includes an anonymous survey to employees and a specific evaluation of the company's corporate culture, assessing the practices, policies, and HR and leadership culture of the organization. Taking everything into account, 94% of Canadian employees stated they would say this is a great place to work, with 96% stating they are treated fairly regardless of their gender. "Great Place to Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place to Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. "By successfully earning this recognition, it is evident that Viatris stands out as one of the top companies to work for, providing a great workplace environment for its employees." Viatris Canada Country Manager Jeffrey Long states, "We are very proud to receive this certification. It's a reflection of the inclusive, purpose-driven culture we've built together as a team." About Viatris Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X. About Great Place to Work Certification™ Great Place to Work® Certification™ is the most definitive "employer-of-choice" recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place to Work-Certified. About Great Place To Work ® As the global authority on workplace culture, Great Place to Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place to Work Certified™ or receiving recognition on a coveted Best Workplaces™ List. Learn more at and follow Great Place To Work on LinkedIn, Twitter, Facebook and Instagram. Forward-Looking Statements This statement includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding new product launches. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; Viatris' failure to achieve expected or targeted future financial and operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, tariffs and trade restrictions, inflation and exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.
